Organic Active Ingredients TRIZ Cases

These EGFR compounds combine kinase inhibition with ubiquitin-proteasome degradation to address C797S drug resistance in lung cancer.

Cumbersome skull-fixed head frames complicate pediatric brain delivery; frameless stereotaxy supports precise rAAV2-hAADC dosing.

Novel FAAH inhibitor compounds use heteroaryl substitutions to improve solubility and oral bioavailability while preserving therapeutic activity.

Systematically varied substituents on a pyrazolopyrimidine core target PI3Kγ for cancer and immune-related disorders.

See how phased dienogest and slow EE release support contraception at lower EE doses while reducing peak fluctuations and irregular bleeding.

Localized bicarbonate release from hydrogels neutralizes acidic tumor environments, reducing ion trapping and supporting weak-base chemotherapy.

Sugar moieties and hydrophobic units help dendrimer carriers address low uptake and transfection in non-viral delivery.

Functionalized carriers occupy host-cell receptor sites to limit pathogen attachment while delivering drugs to targeted cells with fewer systemic effects.

Defined XRPD, DSC, and TG-FTIR criteria guide scalable production of Compound (I) while preserving purity and reproducibility across crystalline forms.

Rapid 5-HTP absorption can cause short exposure and peak-related adverse events; a gastroretentive bilayer releases 5-HTP and carbidopa in parallel.

HTR2C polymorphism testing helps identify likely antipsychotic responders, supporting treatment selection for schizophrenia and bipolar disorder.

A universal guide RNA redirects one Cas9 complex to multiple genomic positions, improving setup and scalability for nucleotide-repeat editing.

Lyophilized lipid complexes combine rapid onset with sustained anesthetic release for pain relief across the 2–4-day postsurgical window.

Heterocyclic and cycloalkyl features tune KHK inhibitors to regulate fructose metabolism while limiting tissue asymmetry and toxicity.

Structural diversification of Formula I inhibitors targets the conserved SARS-CoV-2 main protease against mutating coronaviruses.

Subcutaneous injection limits ease of administration; these GLP-1R agonist compounds offer oral or other non-invasive routes while stimulating insulin.

Combining rapamycin with metformin enhances mTORC1 inhibition, enabling lower rapamycin dosing to reduce long-term side effects.

Enteral delivery uses milk-derived exosomes to carry miRNA and TGF-β to intestinal cells, reducing inflammation and avoiding parenteral risks.

Solvent recrystallization develops piperazine crystal forms with improved solubility and stability for pharmaceutical formulation.

Staufen1-regulating agents target RNA metabolism dysregulation to improve autophagy and reduce toxic protein aggregates.

RepSox and staged BMP4, Activin A, FGF2, and VEGF signaling generate contractile SMCs while limiting phenotype switching and restenosis.

Methotrexate’s limited efficacy and liver and gastrointestinal toxicity are addressed by combining it with pimozide for rheumatoid arthritis.

See how pyridinylpyrimidine inhibitors covalently target FGFR4 Cys552 to improve selectivity and antitumor activity over promiscuous kinase inhibition.

Gel strength enhancers and surfactants create controlled API release, supporting sustained therapeutic levels while reducing injection frequency.

Poor cell entry and off-target kinase activity limit older aldolase inhibitors; these salts target aldolase selectively while activating AMPK.

Selective CHK1 inhibition uses substituted pyrazole-heteroaryl compounds to pursue antitumor activity while reducing hepatotoxicity and hemocyte toxicity.

Novel acetamidylthio β-D-galactopyranoside derivatives inhibit galectin-3 binding to natural carbohydrate ligands for disease treatment.

A pressurized aqueous nanoemulsion uses tuned surfactant, alcohol, and lipophilic ratios to preserve vesicle size across temperature stress.

Conventional rAAVs often require high doses for non-liver tissues; engineered muscle-targeting moieties improve delivery while reducing liver toxicity.

Segmented gene panels sequence relevant hereditary cancer genes to balance risk-assessment precision, processing time, and sequencing complexity.

Natural-material variation can destabilize formula efficacy; defined active-ingredient ranges and HPLC testing improve batch consistency.

Novel heterocyclic derivatives modify BCL-2 inhibitor structure to improve solubility and bioavailability while preserving tumor-regression activity.

Modified Formula I compounds target α4β3δ GABAA receptors as positive allosteric modulators for CNS-related disorders.

Cyclophellitol-inspired pseudo-disaccharides target HPSE with nanomolar potency while limiting pleiotropic off-target effects.

Low GLP-1 permeability limits oral bioavailability; this SNAC-salt composition promotes gastrointestinal absorption while improving dissolution and stability.

Dense tumor stroma can block nanoparticle uptake; FAK-siRNA priming helps CRISPR editors reach tumors for gene editing.

Delgocitinib cream targets JAK3-mediated inflammatory signaling in FFA through a simple topical treatment approach.

Anti-CD2 antibodies and donor bone marrow induce transient mixed chimerism to support graft tolerance without long-term immunosuppression.

Sickle cell blockages and impaired blood flow are addressed by isoquercetin, vitamins B3 and C, and optional folic acid targeting PDI.

Resistance to single-kinase treatments is addressed with diaryl macrocycles that inhibit MET, ALK, AXL, TRK, JAK, and ROS1 signaling.

A lipid-based oral composition transports therapeutic agents across the blood-brain barrier to support brain health and function.

Small-molecule cGAS inhibitors curb inflammatory cytokine production to limit chronic inflammation and tissue damage.

Retinoic acid structural changes support neurite growth and neural cell regeneration while maintaining low cytotoxicity.

Novel substituted glucocorticoid compounds and prodrugs modulate receptor activity to expand treatment options for autoimmune and inflammatory diseases.

Esterifying CBDA at its carboxylic acid group improves stability while supporting treatments for joint, skin, gastrointestinal, and metabolic disorders.

Nasal delivery combines creatine fatty esters, omega-3 fatty acids, and glycerides to bypass the blood-brain barrier in CTD.

High humidity destabilizes Compound 1; crystalline fumarate and hemifumarate salts reduce hygroscopicity while preserving purity for storage.

A dual-layer tablet delivers rapid ibuprofen onset and sustained analgesic efficacy for up to 24 hours after administration.

Conventional therapies often miss underlying metabolic dysfunction; MCT1-transported N-acetyl-L-leucine enters cells to balance lactate and support broader symptom relief.

Genistein sensitizes tumor cells to high-LET proton radiation, enabling lower doses while limiting damage to healthy tissues.